Abstract
Advancements in nanotechnology and cellular biotechnology are revolutionizing skin cancer treatment. Nanotechnology enables smart nanoparticles for precise drug delivery, enhanced imaging, and real-time treatment monitoring, targeting tumors with high specificity and improving outcomes. Theranostic systems further personalize therapy by combining treatment with diagnostics. Cellular biotechnology, especially through gene editing and synthetic biology, offers new cancer therapies, with techniques like CRISPR-Cas9 refining immune-based treatments such as CAR-T cells. These innovations are steering skin cancer therapy toward more personalized and effective approaches. However, challenges in safety, scalability, and regulation remain. Addressing these through interdisciplinary collaboration and robust regulatory frameworks is crucial, particularly for the integration of nanotechnology and cellular biotechnology in combination therapies for advanced or resistant skin cancers.
Get full access to this article
View all access options for this article.